Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.

Blood Adv · 2023 · PMC10368781 · PMID 37058477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Accordingly, when compared with HoWTs, patients carrying variant genotypes of either gene ( ABCB1 or VEGF-A ) showed a trend toward deeper MRD clearance via RQ-PCR in the BM after 6 months of LEN ( supplemental Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.